Christa C Chrovian

This inventor holds 23 USPTO granted patents and 7 published patent applications, plus 5 CIPO patents and 8 EPO patents, primarily in GluN2B Receptor Modulators. Top assignee: Janssen Pharmaceutica Nv. Active years: 2011-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christa C Chrovian. Retrieved from https://idiyas.com/inventor/christa-c-chrovian

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 7)

% Patents Active = 87.0

CIPO Patents = 5 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 10)

Average Co-Inventor Count = 9.3

ph-index = 9

Forward Citations = 199(Granted Patents)

Location History:

San Diego, CA (US) (2011 - 2013)
La Jolla, CA (US) (2015 - 2023)

Company Filing History:

23 out of 2,101

Janssen Pharmaceutica Nv

patents

Years Active: 2011-2025

Loading Chart...

Areas of Expertise:

P2X7 Modulators

GluN2B Receptor

Leukotriene A4 Hydrolase

Substituted Pyrazolo-Pyridine

Thiazolopyridin

1H-Imidazo

1,2,3-Triazoles

4-Azaindoles

Drug Discovery

Pharmacology

NMDA Modulators

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12338243 - P2X7 modulators (2025-06-24),

2. 12247027 - P2X7 modulators (2025-03-11),

3. 12172997 - Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators (2024-12-24),

4. 11820770 - P2X7 modulators (2023-11-21),

5. 11759455 - Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators (2023-09-19),

6. 11618750 - Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators (2023-04-04),

7. 11530210 - Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators (2022-12-20),

8. 11225478 - P2X7 modulators (2022-01-18),

9. 11207298 - Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators (2021-12-28),

10. 10766880 - Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators (2020-09-08),

11. 10703749 - P2X7 modulators (2020-07-07),

12. 10617676 - Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GluN2B receptor modulators (2020-04-14),

13. 10377753 - Substituted 4-azaindoles and their use as GluN2B receptor modulators (2019-08-13),

14. 10233173 - Substituted 1,2,3-triazoles as NR2B-selective NMDA modulators (2019-03-19),

15. 10150765 - P2X7 modulators (2018-12-11),

Title: Christa C. Chrovian: Innovator in Pharmaceutical Compounds

Introduction: Christa C. Chrovian, based in La Jolla, California, is a prominent inventor with a remarkable portfolio of 22 patents. His work focuses on advancing pharmaceutical compounds, particularly those that modulate specific receptors vital for various disease treatments.

Latest Patents: Among his latest innovations are two notable patents. The first is directed toward P2X7 modulators, which includes compounds of Formulas (I, IIa, and IIb) and encompasses pharmaceutical compositions utilizing these compounds. The second patent involves substituted pyrazolo-pyridine amides designed for use as GluN2B receptor modulators. This invention highlights the potential for these compounds to be applied in therapeutic contexts, particularly for conditions linked to GluN2B receptor activity.

Career Highlights: Christa Chrovian is associated with Janssen Pharmaceutica NV, where he contributes significantly to the research and development of novel pharmaceutical solutions. His input in creating compounds that effectively target specific receptor pathways marks a significant advancement in the field of drug development.

Collaborations: Throughout his career, Chrovian has collaborated with notable professionals, including Michael Anthony Letavic and Akinola Soyode-Johnson. These partnerships have helped facilitate the development of innovative therapeutic compounds and strengthened research efforts within Janssen Pharmaceutica NV.

Conclusion: Christa C. Chrovian stands out as an influential inventor in the pharmaceutical industry, with a strong focus on innovative compounds that address critical medical needs. His extensive patent portfolio and collaborative efforts demonstrate his commitment to advancing healthcare through scientific innovation.

Profile summary based on public USPTO records.